Treatment patterns of menopausal hormone therapy in South Korea: a nationwide cohort study.

IF 3.2 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Climacteric Pub Date : 2025-07-24 DOI:10.1080/13697137.2025.2524165

Sungwook Chun, Kyungyeon Jung, Bin Hong, Ju-Young Shin, Ji Young Lee

{"title":"Treatment patterns of menopausal hormone therapy in South Korea: a nationwide cohort study.","authors":"Sungwook Chun, Kyungyeon Jung, Bin Hong, Ju-Young Shin, Ji Young Lee","doi":"10.1080/13697137.2025.2524165","DOIUrl":null,"url":null,"abstract":"Objective: Menopausal hormone therapy (MHT) is the most effective treatment for menopausal symptoms. While guidelines recommend an individualized risk-benefit assessment of MHT, real-world studies on use of MHT are limited.Method: Nationwide claims data in South Korea (2015-2020) were used to assess the prevalence of hospital visits for menopausal symptoms and use of MHT among women aged 40-59 years. MHT was classified into three classes including estrogen therapy (ET), estrogen plus progestogen therapy (EPT) and tibolone, with routes of administration categorized as systemic (oral, transdermal) and local (transvaginal). A longitudinal study was conducted to evaluate treatment patterns of MHT.Results: Approximately 9% of women visited hospitals for menopausal symptoms, with fewer than half prescribed MHT. Of 1,774,674 women with menopausal symptoms, 1,036,294 were prescribed MHT: 89,237 patients were started on systemic ET, 300,999 on systemic EPT, 306,538 on tibolone and 378,764 on local ET. Use of tibolone and local ET increased over time, while systemic ET and EPT decreased. Systemic MHT was discontinued after an average of 13.2 months, while local MHT was discontinued after 2.4 months.Conclusion: Despite guidelines recommending MHT for treating menopausal symptoms, many women remain untreated and continued MHT for an average of only 1 year.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-8"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2025.2524165","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Menopausal hormone therapy (MHT) is the most effective treatment for menopausal symptoms. While guidelines recommend an individualized risk-benefit assessment of MHT, real-world studies on use of MHT are limited.

Method: Nationwide claims data in South Korea (2015-2020) were used to assess the prevalence of hospital visits for menopausal symptoms and use of MHT among women aged 40-59 years. MHT was classified into three classes including estrogen therapy (ET), estrogen plus progestogen therapy (EPT) and tibolone, with routes of administration categorized as systemic (oral, transdermal) and local (transvaginal). A longitudinal study was conducted to evaluate treatment patterns of MHT.

Results: Approximately 9% of women visited hospitals for menopausal symptoms, with fewer than half prescribed MHT. Of 1,774,674 women with menopausal symptoms, 1,036,294 were prescribed MHT: 89,237 patients were started on systemic ET, 300,999 on systemic EPT, 306,538 on tibolone and 378,764 on local ET. Use of tibolone and local ET increased over time, while systemic ET and EPT decreased. Systemic MHT was discontinued after an average of 13.2 months, while local MHT was discontinued after 2.4 months.

Conclusion: Despite guidelines recommending MHT for treating menopausal symptoms, many women remain untreated and continued MHT for an average of only 1 year.

查看原文本刊更多论文

韩国绝经期激素治疗的治疗模式：一项全国性队列研究。

目的：绝经期激素治疗（MHT）是治疗绝经期症状最有效的方法。虽然指南建议对MHT进行个体化的风险-收益评估，但关于MHT使用的实际研究有限。方法：使用韩国2015-2020年的全国索赔数据来评估40-59岁女性因更年期症状和MHT使用而就诊的患病率。MHT分为雌激素治疗（ET）、雌激素加孕激素治疗（EPT）和替博酮三大类，给药途径分为全身（口服、经皮）和局部（经阴道）。我们进行了一项纵向研究来评估MHT的治疗模式。结果：大约9%的妇女因更年期症状去医院就诊，只有不到一半的人开了MHT。在1,774,674名有更年期症状的女性中，1,036,294名患者接受了MHT治疗：89,237名患者开始接受全身ET治疗，300,999名患者接受全身EPT治疗，306,538名患者接受替博龙治疗，378,764名患者接受局部ET治疗。随着时间的推移，替博龙和局部ET的使用增加，而全身ET和EPT的使用减少。全身MHT平均在13.2个月后停止，而局部MHT在2.4个月后停止。结论：尽管指南推荐MHT治疗更年期症状，但许多妇女仍未接受治疗，平均仅持续了1年。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Climacteric 医学-妇产科学

CiteScore

1.70

自引率

7.10%

发文量

审稿时长

1 months

期刊介绍： Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.